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Are probiotic treatments useful in Fibromyalgia Syndrome or Chronic Fatigue 
Syndrome patients? A systematic review 
ABSTRACT 
Background. Evidence suggests that the gut microbiota might play an important role in 
fibromyalgia syndrome (FMS) and chronic fatigue syndrome (CFS). 
Aim. Our goal is to systematically review the reported effect of probiotic treatments in 
patients diagnosed with FMS or CFS. 
Methods. A systematic review was carried out using 14 databases (PubMed, Cochrane 
Library, Scopus, PsycINFO, and others) in February 2016 to search for randomized 
controlled trials (RCTs) and pilot studies of CFS or FMS patient, published in the last 
ten years (from 2006 to 2016). The Jadad scale was used to asseverate the quality of the 
clinical trials considered. 
Results. Two studies (n=83) met the inclusion criteria, which were performed in CFS 
patients and both studies were considered as a “HIGH range of quality score”. The 
administration of Lactobacillus casei strain Shirota in CFS patients, over the course of 8 
weeks, reduced anxiety scores. Likewise, this probiotic changed the faecal composition 
following 8 weeks of treatment. Additionally, the treatment with Bifidobacterium 
infantis 35624 in CFS patients, during the same period, reduced inflammatory 
biomarkers. The evidence about the usefulness of probiotics in CFS and FMS patients is 
remains limited. 
Conclusions. The studied strains of probiotics have demonstrated a significant effect on 
modulating the anxiety and inflammatory processes in CFS patients. However, more 
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experimental research, focusing mainly on the symptoms of the pathologies studied, is 
needed. 
Keywords: probiotics; fibromyalgia; chronic fatigue syndrome; gut-brain axis; 





Fibromyalgia syndrome (FMS) is a chronic, generalized and diffuse pain 
disorder accompanied by symptoms such as morning stiffness or rest, fatigue, 
depression and sleeping disorders, which etiology is still unknown (Wolfe et al., 1990, 
2010). The European population has different prevalence rates of FMS, from 1.4% in 
France to 3.7% in Italy (Branco et al., 2010). Similar prevalence data have been found 
in other countries such as North America with an estimated prevalence rate ranging 
from 2.0% to 3.3% (reviewed in Jones et al., 2015). However, this rate of prevalence 
could be increased in relation to the diagnosis criteria used. For example, with the 
modified 2010 criteria (Wolfe et al., 2011), the prevalence rate increases to 5.4%, with a 
ratio of females to males of 2.3:1 (Jones et al., 2015). 
FMS is often associated with other somatic syndromes such as chronic fatigue 
syndrome (CFS), a condition characterized by 6 months or more of persisting or 
relapsing fatigue caused by an over-production of pro-inflammatory cytokines; the CFS 
prevalence rate ranges from 3 to 20% (Penfold, St. Denis, & Mazhar, 2016). For 
example, while all patients with CFS present with high levels of fatigue, there is 
considerable overlap in patients with FMS, with a percentage of 86% reporting fatigue 
as well (Aaron, Burke, & Buchwald, 2000). In addition, Aaron and Buchwald (2001) 
and Buchwald and Garrity (1994), found that between 35% to 70% of CFS patients met 
the criteria for FMS, reporting a considerable co-occurrence with CFS (Odds Ratio 
(OR)=23.2) (Kanaan, Lepine, & Wessely, 2007). 
Although the most common symptom in FMS is pain and in CFS is fatigue, a 
high prevalence of gastrointestinal symptoms has been reported in both disorders 
(Aaron et al., 2000). In fact, 81% of FMS patients reported normal alternating with 
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irregular bowel pattern, and 63% had alternating diarrhoea and constipation 
(Triadafilopoulos, Simms, & Goldenberg, 1991). Similarly, 32.2% of CFS patients used 
various gastrointestinal drugs in comparison with control subjects (14.3%), indicating 
an OR of 2.67 (Jones, Nisenbaum, & Reeves, 2003). 
Conversely, between 32% to 80% of patients with FMS met the criteria for 
irritable bowel syndrome (IBS), a common functional disorder of the gastrointestinal 
tract (Aaron & Buchwald, 2001; Riedl et al., 2008; Sperber et al., 1999; Whitehead, 
Palsson, & Jones, 2002), with considerable comorbidities (OR from 1.8 to 5.3) (Kanaan 
et al., 2007). Likewise, between 58 and 92% of patients with CFS met criteria for IBS 
(Aaron & Buchwald, 2001). 
Cognitive and affective deficits, such as nervousness, memory loss, 
forgetfulness and confusion, have been documented in patients with CFS or FMS 
(Glass, 2008; Joyce, Blumenthal, & Wessely, 1996). Interestingly, it was demonstrated 
that the severity of these neurological and cognitive deficits is related to reduced levels 
of Bifidobacterium spp. and increased levels of Enterococcus spp, which have been 
detected in FMS as well as in CFS (Butt, Dunstan, McGregor, & Roberts, 2001). In 
addition, CFS patients show alterations in gut microbiota suggesting a probable link 
between intestinal colonization of gram-positive facultative anaerobic D-lactic acid 
bacteria and symptom expression, these bacteria have been reported to be associated 
with cognitive dysfunction and neurological impairment in patients with intestinal 
bacterial overgrowth (Sheedy et al., 2009).  Pimentel and colleagues (2003) found an 
abnormal lactulose breath test in FMS patients (78%), which suggested bacterial 
overgrowth of the small intestine (SIBO), which represents one form of alteration of the 
normal gut microbiota characterized by a qualitative and quantitative change of the 
bacterial colonies that inhabit the small intestine. Under normal conditions, the upper 
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tract of the small intestine is mainly colonized by Gram-positive bacteria whose counts 
do not exceed 103 organisms/mL. However, in the case of SIBO, the count of these 
colonies either increases to or exceeds 105 –106 organisms/mL (Slim, Calandre, & Rico-
Villademoros, 2015). A later research study by Pimentel and colleagues (2004) 
demonstrated that 100% of FMS patients were diagnosed with SIBO compared to 84% 
of subjects with IBS and 20% of healthy subjects.  
Other facts indicating that the gastrointestinal system is affected in FMS patients 
may include hipersensivity to food components, celiac disease, non-celiac gluten 
sensitivity, lactose intolerance and FODMAPs (Fermentable oligo-, di-, mono-
saccharides and polyol) (Slim et al., 2015). An increase in secretory immunoglobulin A 
(sIgA) has also been observed in FMS (Michalsen et al., 2005), which is related to 
fatigue, major depression and gastrointestinal symptoms (Maes, Kubera, & Leunis, 
2008). 
All of the aforementioned findings demonstrate the relevance of microbiota in 
FMS and CFS, pointing to the potential use of probiotics in these syndromes, as it has 
been recently suggested by several authors (Galland, 2014; Lakhan & Kirchgessner, 
2010; Slim et al., 2015). Probiotics are live microorganism that, when administered in 
adequate amounts, confer a health benefit to the host (FAO/WHO, 2001). Several 
authors suggest that the effects of probiotics may be genus-specific or depend on the 
species or strain or the dose used (Umbrello & Esposito, 2016). IBS is one of the 
populations with more evidence from probiotic treatments (Didari, Mozaffari, Nikfar, & 
Abdollahi, 2015; Tiequn, Guanqun, & Shuo, 2015). In fact, pain and symptom severity 
scores in IBS patients have been reported to be reduced after the consumption of 
probiotics. Similarly, probiotics have been demonstrated as also useful in patients with 
SIBO (Khalighi et al., 2014). In recent years, the interest of the role of probiotics in 
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mood and emotional modulation has increased. Mood and emotional symptoms are also 
present in patients with FMS and CFS and may be affected by probiotics (Benton, 
Williams, & Brown, 2007; Messaoudi, Lalonde, et al., 2011; Messaoudi, Violle, et al., 
2011; Steenbergen, Sellaro, van Hemert, Bosch, & Colzato, 2015). Probiotic 
effectiveness in improving depression and anxiety is produced through the connection 
between the gut and the brain or gut-brain axis (Carabotti, Scirocco, Maselli, & Severi, 
2015; Cryan & O’Mahony, 2011; Cryan & Dinan, 2012; De Palma, Collins, Bercik, & 
Verdu, 2014; Diaz Heijtz et al., 2011; Maes et al., 2008; Sherwin, Rea, Dinan, & Cryan, 
2016). 
To summarize, the high comorbidity between FMS and CFS with 
gastrointestinal pathologies, such as IBS, as well as the high gastrointestinal 
symptomatology presented by these patients has been documented. In addition, several 
other symptoms presented in FMS and CFS patients, such as anxiety or depression, 
have been improved through treatment with probiotics in other populations. Altogether, 
these findings support our hypothesis that the probiotics could improve FMS and CFS 
symptoms. A better understanding of the probiotic effects in these pathologies is 
required to develop integrative approaches for patient care. Therefore, the aim of this 
study was to systematically review the reported effect of probiotic treatments in patients 
diagnosed with FMS or CFS.  
METHODS 
In February 2016, a systematic review of clinical trials and pilot studies was 
conducted. The process of reviews adheres to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009). The 
Cochrane Handbook for Systematic Reviews (Higgins & Green, 2011) was also 
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consulted. The search was limited to studies published in the last ten years, from 2006 
to 2016. The protocol for this review was not registered. 
Research Question 
The follow structured, Patient-Intervention-Outcomes question (PIO) (Stone, 
2002) was used as follows: Are probiotics able to reduce or improve symptoms in FMS 
or CFS patients? 
Data sources/Information sources 
The search was conducted in a total of 14 electronic bibliographic databases, due 
to the novelty and multidisciplinary approach of the topic. The search for clinical trials 
and pilot studies using probiotics for FMS or CFS was conducted using the following: 
Cochrane Library, ProQuest, Turning Research Into Practice (TRIP), Web of Science, 
PubMed, The Cumulative Index to Nursing and Allied Health Literature (CINAHL), 
Scopus, PsycINFO, ScienceDirect, AGRICOLA, DialnetPlus, LILACS, Scielo, 
National Institute for Health and Care Excellence (NICE), and the searches were 
complemented using the snowball strategy.  
To identify the potential studies in electronic databases, structured by the PIO 
research question, the following keywords (MeSH or DeCS) were used: patients key 
words (“fibromyalgia” OR “fatigue syndrome, chronic”), AND intervention keywords 
(“probiotics” OR “lactobacillus” OR “bifidobacterium”), AND outcomes keywords 
(“pain” OR “depression” OR “anxiety” OR “fatigue” OR “muscle rigidity” OR “sleep 
wake disorders” OR “headache” OR “migraine without aura” OR “paresthesia”) in the 
title, key words or abstract. After a preliminary search, it was decided to exclude 
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outcome keywords in the definite searches because they limited too much of the 
available research.  
Study Eligibility Criteria 
 The following inclusion criteria were used in this review: (1) randomized 
controlled trials (RCTs) or pilot studies in humans; (2) participants diagnosed with FMS 
or CFS; (3) publications from January 1, 2006 to February 1, 2016; (4) published in 
English or Spanish; and (5) adult participants aged 18 years or older. 
Study Selection and Methodologic Quality 
The two first authors carried out the databases search. Next, the studies were 
selected by the two same authors who, independently and in duplicate, reviewed all 
studies. If consensus could not be achieved, the third author was consulted and asked 
for a recommendation to include it or not. The selected data were discussed at a face-to-
face meeting of all authors (reviewers); all authors also discussed the extracted data.  
Full texts of potentially relevant articles were independently appraised by the 
same two authors using the Jadad Scale for Reporting Randomized Controlled Trials, a 
checklist with five simple items that help to evaluate the quality of RCTs in a simple 
way (Clark et al., 1999). In addition, this scale contains many of the important elements 
that have empirically been demonstrated to correlate with bias, and it has known 
reliability and external validity (Halpern & Douglas, 2005). The scoring is based on the 
quality of randomization, double blinding, and losses to follow-up and establishes a 
score of greater than 3 points as high quality and less than 3 points as low quality (Jadad 
et al., 1996). 
Data Extraction and Data Synthesis 
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The major categories of the coded variables include the following: (1) reference, 
(2) number of enrolled patients, (3) probiotics used, (4) outcomes and (5) duration of 
the intervention. 
 Initially we planned to report the effectiveness of probiotics by using descriptive 
statistics. However, the few results and the heterogeneity of outcomes measures used 
across the studies made the meta-analysis impossible. Thus, we decided to report the 
effectiveness of probiotic treatments by using narrative summaries. 
Complementary Search 
Complementary searches were performed about other uses of specific probiotic 
strains used in FMS or CFS patients (Lactobacillus casei strain Shirota and 
Bifidobacterium infantis 35624). A brief (synthesis) of these results can be found in 
Table S1 and Table S2. 
RESULTS 
From a total of 537 eligible articles found in our initial search, we finally 
included 2 articles that met the inclusion criteria. The review and selection processes are 
detailed in Figure 1.  
Insert Figure 1 around here 
Figure 1. Flowchart of literature search carried out for this review.  
Included studies 
A total of 2 primary research papers (Groeger et al., 2013; Rao et al., 2009) were 
included in this review (detailed information is demonstrated in Table 1). We did not 
identify any clinical trials. These 2 articles could be considered pilot studies, although 
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only Rao et al. (2009) identified their study as a pilot study. Both studies were 
randomized and double-blinded. They included 4 groups (2 intervention and 2 control). 
Although the study of Groeger and colleagues (2013) included other pathologies and a 
healthy subject group, in our review, we focused only on the group with CFS patients. 
Neither of the included studies was focused on FMS patients. Eighty-three patients 
diagnosed with CFS, 8 men and 75 women randomly assigned, participated in both 
studies (the sample sizes ranged from 35 (Rao et al., 2009) to 48 (Groeger et al., 2013)). 
All of the included studies clearly described how the sample size was calculated. The 
age range of the participants was 18 to 65 years old. The studies were conducted in 
Ireland and Canada and were published in English. 
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(2.410  CFU per day) 
- Depression: BDI 
- Anxiety: BAI 
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(1x1010 CFU per day) 
- Inflammatory 
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EXP: Treatment group; CON: Placebo group; CFU: colony-forming units; BDI: Beck 
depression Inventory; BAI: Beck Anxiety Inventory; CRP: C-Reactive Protein; IL-6: 
Interleukin 6; TNF-α: Tumor necrosis factor 
Methodologic Qualities of Studies: risk of bias and quality of evidence 
 Table 2 presents the assessment of methodological quality and potential risk of 
bias in the included studies using the Jadad Scale. The study by Rao et al. (2009) 
obtained a score of 4 points, while the study by Groeger et al. (2013) obtained 3 points; 
thus, both studies were considered as a “HIGH range of quality score”. 
Table 2. Quality Appraisal based on Jadad Scale for RCTs (n = 2). 
 Studies Retrieved for Quality Appraisal 
Appraisal Criteria Rao et al., 2009 Groeger et al., 2013  
1.  Was randomization mentioned? Y Y 
2.  Was method of randomization appropriate? U U 
3.  Was blinding mentioned? Y Y 
4.  Was method of blinding appropriate? Y Y 
5.  Was the fate of all patients in the trial known? Y U 
Scores 4 3 




Effects of intervention 
• Specific intervention 
The probiotics used in the included studies were the Lactobacillus casei strain 
Shirota (LcS) (Rao et al., 2009) and Bifidobacterium infantis 35624 (Groeger et al., 
2013). The duration of the treatment for both studies was 8 weeks. More details about 
the use of these probiotics in other pathologies can be found in Table S1 and Table S2, 
as result of a complementary search. 
• Gut composition 
In the study of Rao et al.(2009) the faecal composition of Bifidobacteria and 
Lactobacillus was assessed pre- and post- treatment. Compared to the placebo control 
group, the probiotic group demonstrated moderate increases in total faecal aerobes and 
anaerobes and significant increases in total faecal Bifidobacteria and Lactobacillus. 
Specifically, in the placebo group only 37.5% of subjects demonstrated an increase in 
Bifidobacteria, whereas 62.5% of participants demonstrated a decrease. In the probiotic 
group, 73.7% of the faecal samples increased in Bifidobacteria, and 26.3% decreased 
after the treatment.  
Concerning Lactobacillus, in the placebo group, 43.8% increased their levels, while 
56.2% decreased. In the probiotic group, 73.7% increased, 21% decreased, and 5.3% 
had no change.   
Summarizing, the total faecal aerobes in comparison with the baseline decreased in 
the placebo group, while they increased in the probiotic group. With respect to total 
anaerobes, in the placebo group, they remained almost unchanged, while in the 
probiotic group, the total increased after the treatment. 
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• Anxiety and depression 
According to the research of Rao et al.(2009), the anxiety of CFS patients was 
evaluated by the Beck Anxiety Inventory (BAI), and a significant decrease (p=0.011) 
was found in the anxiety scores in the probiotic group, compared with the placebo 
group. However, no significant difference (p=0.292) in depression, assessed by the 
Beck Depression Inventory (BDI), was observed among those taking probiotics. 
• Inflammatory processes 
Groeger and et al. (2013) reported that the oral administration of Bifidobacterium 
infantis 35624 modulated the cytokine milieu across non-gastrointestinal inflammatory 
disorders. Specifically, following the administration of the probiotic, they directed their 
analysis of plasma levels of C-reactive protein (CRP), a biomarker of inflammation, and 
the following peripheral pro-inflammatory cytokines: TNF-α and IL-6. Probiotic-fed 
CFS patients demonstrated reduced plasma levels of CRP (p=0.0285), TNF-α (p = 
0.0214) and IL-6 (p = 0.054) compared to placebo-fed CFS patients. When comparing 
the probiotic-feeding effect to baseline (pre-treatment plasma levels), they also reported 
a significant post-treatment reduction in the plasma levels of CRP (p= 0.0393), TNF-α 
(p =0.0129) and IL-6 (p = 0.0021) in CFS patients. Contrastingly, in the placebo-fed 
CFS group, the plasma CRP and TNF-α levels increased slightly, while the plasma IL-6 
levels remained unchanged after eight weeks of treatment. 
Therefore, the individual’s biomarkers (CRP, TNF-α, and IL-6; represented by 
percentage changes from baseline) demonstrated that 71% of CFS patients in the 
probiotic group displayed decreased levels at week 8, whereas in the placebo group, 
only 11% of participants demonstrated a decrease in these levels at the same period.  
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• Adverse effects and safety of probiotics 
Rao et al. (2009) demonstrated that the LcS probiotic powder was well tolerated and 
that there were no significant adverse events reported in the probiotic group or in the 
placebo group. Groeger et al.(2013) did not assess whether the Bifidobacterium infantis 




This systematic review aimed to critically appraise and synthesize the existing 
empirical evidence on the effectiveness of probiotic administration for the treatment of 
FMS or CFS symptoms. To the best of our knowledge, this is the first systematic review 
of the effects of probiotics on these syndromes. 
The available research concerning the potential usefulness of probiotic treatment 
for FMS or CFS is limited. Nevertheless, it seems, from the results of the two studies 
reviewed here (Groeger et al., 2013; Rao et al., 2009), that some probiotic strains might 
improve the symptoms of anxiety and inflammation in these populations. 
However, it is worth noting that all the included studies were conducted in CFS 
patients and that neither of the studies were carried out in FMS patients. Additionally, 
neither of these studies were focused on fatigue, the core symptom of CFS. 
Interestingly, in a study excluded as an exploratory study, Sullivan, Nord and Evengård 
(2009) evaluated the effect of Lactobacillus paracasei ssp. Paracasei F19, 
Lactobacillus acidophilus NCFB 1748 and Bifidobacterium lactis Bb12 on fatigue and 
physical activity in 15 patients diagnosed with CFS. Their results demonstrated that 
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participants improved their neurocognitive functions by subjectively reporting that their 
short-term memory and capacity to concentrate (p=0.040) was affected from baseline to 
the end of the follow-up (day 72), but no significant differences in fatigue or in the 
remaining variables measured (health and physical activity) were observed. Another 
study carried out in patients with spondyloarthritis (Jenks et al., 2010), using a 
combination of probiotics (Streptococcus salivarius K12, Bifidobacterium lactis LAFTI 
B94, and Lactobacillus acidophilus LAFTI L10) for 12 weeks, patients demonstrated no 
significant benefit over placebo concerning fatigue. Finally, an improvement trend in 
fatigue (p<0.10) was observed when colorectal cancer patients who received a 12-week 
probiotic intervention containing Lactobacillus rhamnosus combined with Lactobacillus 
acidophilus were compared to a placebo group (Lee et al., 2014). 
Although only CFS patients improved in their anxiety scores after receiving 
probiotics (Rao et al., 2009), there is much more evidence from other populations 
concerning both anxiety and depression. For example, Steenbergen et al. (2015) 
concluded that the intake of a multispecies probiotic for 4 weeks in healthy subjects 
could reduce negative thoughts associated with a sad mood, suggesting that the 
probiotic supplementation was a potential preventive strategy for depression. Another 
study carried out by Messaoudi, Lalonde, et al. (2011) in the general population 
demonstrated that Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 
taken in combination for 30 days decreased the global scores on the Hospital Anxiety 
and Depression (HAD) scale. Similar results were also found in a population with low 
urinary free cortisol levels at baseline (Messaoudi, Violle, et al., 2011). Finally, 
Akkasheh and colleagues (2016) observed that an 8-week probiotic administration 
(containing Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium 
18 
 
bifidum) had beneficial effects on BDI scores (p=0.001) among patients with major 
depressive disorder compared with the placebo group.  
Several studies have demonstrated beneficial effects from probiotics in IBS, a 
syndrome with a great comorbidity with CFS and FMS (Aaron & Buchwald, 2001; 
Kanaan et al., 2007). Lorenzo-Zúñiga et al.(2014) observed that a new combination of 
three different probiotic bacteria ((two Lactobacillus plantarum (CECT7484 and 
CECT7485) and one Pediococcus acidilactici (CECT7483)) was superior to a placebo 
in improving IBS-related quality of life in patients with IBS and diarrhoea. Similar 
results were found with prebiotics, demonstrating a significant effect (p<0.05) in 
anxiety scores but not in depression level, both assessed by the HAD (Silk, Davis, 
Vulevic, Tzortzis, & Gibson, 2009). Nevertheless, Dapoigny et al.(2012), using the 
same scale, did not observe any clinical difference between the probiotic group 
(Lactobacillus caseirhamnosus LCR35) and the placebo group. With respect to pain, 
probiotics (Lactobacillus rhamnosus GG) significantly reduced the frequency and 
severity of abdominal pain in children with IBS (Francavilla et al., 2010) and appeared 
to moderately increase the treatment success (Gawrońska, Dziechciarz, Horvath, & 
Szajewska, 2007). This reduction of pain after probiotic treatment was also observed in 
patients with rheumatoid arthritis. In fact, Mandel, Eichas and Holmes (2010) found that 
the probiotic group (Bacillus coagulans GBI-30, 6086) experienced a borderline 
statistically significant improvement in the patient pain assessment score (p=0.052) and 
a statistically significant improvement in the pain scale (p=0.046) in comparison with 
the placebo group. Additionally, and in accordance with the results obtained by Groeger 
et al. (2013), the probiotic group demonstrated reduced CRP levels compared with the 
placebo group. Finally, it is worth noting that Ringel-Kulka et al. (2014) provide a 
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possible mechanism of action by which probiotics (L-NCFM) modulate pain sensation 
in humans through opioid-mediated pathways.  
In recent years, accumulating evidence has suggested that probiotics may have a 
positive effect on health through the brain-gut axis (Bercik & Collins, 2014; De Palma 
et al., 2014; Diaz Heijtz et al., 2011; Sherwin et al., 2016). Communication in this axis 
would take place via the following three different pathways: neural (mainly by the 
vagus nerve and the enteric nervous system), endocrine (cortisol) and immune 
(cytokines) (Carabotti et al., 2015; Cryan & Dinan, 2012; Cryan & O’Mahony, 2011; 
Petschow et al., 2013; Zhou & Foster, 2015). Several proposed mechanisms of action of 
probiotics include competition against the pathogenic bacteria that bind to the intestinal 
epithelial cells, enhancement of the intestinal epithelial barrier function, inhibition of 
pathogen growth by the secretion of antimicrobial peptides, and enhancement of the 
production of serum IgA as possible mechanisms (Hardy, Harris, Lyon, Beal, & Foey, 
2013; Upadhyay & Moudgal, 2012). It has also been recently suggested that probiotics 
may affect the central nervous system via the BGA (i) by enhancing the production and 
delivery of neuroactive substances, such as gamma-amino butyric acid (GABA), 
serotonin, dopamine and acetylcholine; (ii) by the vagus nerve (Dinan, Stanton, & 
Cryan, 2013) and (iii) by decreasing pro-inflammatory cytokines, which are able to 
cross the blood-brain barrier and elicit mood and behavioural changes (Hardy et al., 
2013). For instance, some probiotics have been demonstrated to induce an elevation in 
tryptophan levels in plasma (Desbonnet, Garrett, Clarke, Bienenstock, & Dinan, 2008), 
which is a precursor of serotonin. Serotonin has been implicated in emotional processes, 
cognition, motor function and pain, as well as in neuroendocrine functions, such as food 
intake, circadian rhythms and reproductive activity (Martinowich & Lu, 2008). 
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Despite the hypothesis of the usefulness of probiotics in FMS and CFS, this 
systematic review has shown that, till today, the number of clinical trials is too limited 
to conclude that probiotics are useful in these pathologies. This fact is due to the 
unknown etiology and widespread symptoms suffered by these patients. However, these 
results could be increased in the coming years with incoming clinical trials, controlled 
and double blind, such as the one that Roman and colleagues are performing from 2017. 
This review is not free of limitations. There are some methodological limitations 
that we must highlight, the protocol of the review has not been registered. In addition, 
we imposed date restriction (from year 2006 to year 2016), however, this aspect might 
not influence in the results as this topic is very recent. Concerning the databases used, 
we included a large number that increased the number of repeated results. Likewise, we 
used “Lactobacillus” and “Bifidobacterium” as descriptors due to that those are the 
main probiotic strains, but not other strains such as “Streptococcus” or “Pediococcus” 
were included. Nevertheless, these and others probiotic strains are included in the 
descriptor “probiotic”, so that this circumstance may not interfere in the results. 
CONCLUSIONS  
Through this systematic review, we conclude that several probiotic strains 
(Lactobacillus casei strain Shirota and Bifidobacterium infantis 35624) demonstrate 
beneficial effects in CFS patients. However, none of the studies were carried out in 
FMS patients. These reported benefits include decreased anxiety levels and changes in 
the microbiota composition, as well as a reduction in several systematic inflammatory 
biomarkers. A large and exhaustive review of the literature was presented, suggesting 
the possible mechanism involved in these effects. However, due to the reduced number 
of studies included in this review, more research is required to clarify the possible 
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beneficial effects of probiotics for other symptoms of FMS and CFS such as fatigue or 
pain. Taking into account the results obtained with other populations, we also think that 
probiotics might improve emotional and cognitive processes in patients with FMS and 
CFS. Further studies should investigate this issue. 
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